FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3211114462> ?p ?o ?g. }

• W3211114462 endingPage "101251" @default.
• W3211114462 startingPage "101251" @default.
• W3211114462 abstract "Glioblastoma (GBM) is the most common primary brain tumor with a dismal prognosis. The inherent cellular diversity and interactions within tumor microenvironments represent significant challenges to effective treatment. Traditional culture methods such as adherent or sphere cultures may mask such complexities whereas three-dimensional (3D) organoid culture systems derived from patient cancer stem cells (CSCs) can preserve cellular complexity and microenvironments. The objective of this study was to determine if GBM organoids may offer a platform, complimentary to traditional sphere culture methods, to recapitulate patterns of clinical drug resistance arising from 3D growth.Adult and pediatric surgical specimens were collected and established as organoids. We created organoid microarrays and visualized bulk and spatial differences in cell proliferation using immunohistochemistry (IHC) staining, and cell cycle analysis by flow cytometry paired with 3D regional labeling. We tested the response of CSCs grown in each culture method to temozolomide, ibrutinib, lomustine, ruxolitinib, and radiotherapy.GBM organoids showed diverse and spatially distinct proliferative cell niches and include heterogeneous populations of CSCs/non-CSCs (marked by SOX2) and cycling/senescent cells. Organoid cultures display a comparatively blunted response to current standard-of-care therapy (combination temozolomide and radiotherapy) that reflects what is seen in practice. Treatment of organoids with clinically relevant drugs showed general therapeutic resistance with drug- and patient-specific antiproliferative, apoptotic, and senescent effects, differing from those of matched sphere cultures.Therapeutic resistance in organoids appears to be driven by altered biological mechanisms rather than physical limitations of therapeutic access. GBM organoids may therefore offer a key technological approach to discover and understand resistance mechanisms of human cancer cells." @default.
• W3211114462 created "2021-11-08" @default.
• W3211114462 creator A5010165474 @default.
• W3211114462 creator A5010345254 @default.
• W3211114462 creator A5015032940 @default.
• W3211114462 creator A5028896074 @default.
• W3211114462 creator A5034163976 @default.
• W3211114462 creator A5037432177 @default.
• W3211114462 creator A5044388176 @default.
• W3211114462 creator A5089511408 @default.
• W3211114462 date "2022-01-01" @default.
• W3211114462 modified "2023-09-27" @default.
• W3211114462 title "Three-dimensional organoid culture unveils resistance to clinical therapies in adult and pediatric glioblastoma" @default.
• W3211114462 cites W1545028983 @default.
• W3211114462 cites W1891848729 @default.
• W3211114462 cites W1902577542 @default.
• W3211114462 cites W1975957651 @default.
• W3211114462 cites W1992867900 @default.
• W3211114462 cites W2001244335 @default.
• W3211114462 cites W2001544973 @default.
• W3211114462 cites W2010345740 @default.
• W3211114462 cites W2018671779 @default.
• W3211114462 cites W2026480865 @default.
• W3211114462 cites W2030017878 @default.
• W3211114462 cites W2051588629 @default.
• W3211114462 cites W2060551076 @default.
• W3211114462 cites W2079179944 @default.
• W3211114462 cites W2096287682 @default.
• W3211114462 cites W2106675906 @default.
• W3211114462 cites W2107823533 @default.
• W3211114462 cites W2123509170 @default.
• W3211114462 cites W2124078079 @default.
• W3211114462 cites W2146177965 @default.
• W3211114462 cites W2286284214 @default.
• W3211114462 cites W2546901302 @default.
• W3211114462 cites W2744344545 @default.
• W3211114462 cites W2778160201 @default.
• W3211114462 cites W2788735115 @default.
• W3211114462 cites W2790892047 @default.
• W3211114462 cites W2794257073 @default.
• W3211114462 cites W2796407886 @default.
• W3211114462 cites W2802314931 @default.
• W3211114462 cites W2888553759 @default.
• W3211114462 cites W2921471094 @default.
• W3211114462 cites W2922854104 @default.
• W3211114462 cites W2937767865 @default.
• W3211114462 cites W2941179507 @default.
• W3211114462 cites W2942427214 @default.
• W3211114462 cites W2961217357 @default.
• W3211114462 cites W2965589450 @default.
• W3211114462 cites W2992965996 @default.
• W3211114462 cites W2997979341 @default.
• W3211114462 cites W3014253386 @default.
• W3211114462 cites W3019387577 @default.
• W3211114462 cites W3038208268 @default.
• W3211114462 cites W3158981225 @default.
• W3211114462 cites W3165059111 @default.
• W3211114462 cites W3166010079 @default.
• W3211114462 cites W4211220688 @default.
• W3211114462 doi "https://doi.org/10.1016/j.tranon.2021.101251" @default.
• W3211114462 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8551697" @default.
• W3211114462 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34700192" @default.
• W3211114462 hasPublicationYear "2022" @default.
• W3211114462 type Work @default.
• W3211114462 sameAs 3211114462 @default.
• W3211114462 citedByCount "21" @default.
• W3211114462 countsByYear W32111144622022 @default.
• W3211114462 countsByYear W32111144622023 @default.
• W3211114462 crossrefType "journal-article" @default.
• W3211114462 hasAuthorship W3211114462A5010165474 @default.
• W3211114462 hasAuthorship W3211114462A5010345254 @default.
• W3211114462 hasAuthorship W3211114462A5015032940 @default.
• W3211114462 hasAuthorship W3211114462A5028896074 @default.
• W3211114462 hasAuthorship W3211114462A5034163976 @default.
• W3211114462 hasAuthorship W3211114462A5037432177 @default.
• W3211114462 hasAuthorship W3211114462A5044388176 @default.
• W3211114462 hasAuthorship W3211114462A5089511408 @default.
• W3211114462 hasBestOaLocation W32111144621 @default.
• W3211114462 hasConcept C104317684 @default.
• W3211114462 hasConcept C114851261 @default.
• W3211114462 hasConcept C136302470 @default.
• W3211114462 hasConcept C142724271 @default.
• W3211114462 hasConcept C163688615 @default.
• W3211114462 hasConcept C169760540 @default.
• W3211114462 hasConcept C2776194525 @default.
• W3211114462 hasConcept C2777389519 @default.
• W3211114462 hasConcept C2777933648 @default.
• W3211114462 hasConcept C28328180 @default.
• W3211114462 hasConcept C31695470 @default.
• W3211114462 hasConcept C502942594 @default.
• W3211114462 hasConcept C54355233 @default.
• W3211114462 hasConcept C55427017 @default.
• W3211114462 hasConcept C55493867 @default.
• W3211114462 hasConcept C71924100 @default.
• W3211114462 hasConcept C81885089 @default.
• W3211114462 hasConcept C86339819 @default.
• W3211114462 hasConcept C86803240 @default.
• W3211114462 hasConcept C89423630 @default.

• next